TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8250358

Group type: EXPERIMENTAL
Intervention: 25 ml per m2 of body surface area of carbonated 1% lignocaine, 0.25% bupivacaine or a 1 to 1 mixture of both.
Number of subjects: 120

Group type: COMPARATOR
Intervention: 12.5 ml.m‐2 of carbonated 2% lignocaine, 0.5% bupivacaine or a 1 to 1 mixture of both.
Number of subjects: 120
Study: 4025773

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 50
Study: 29682022

Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate 40 mg injected into each level (Group 1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Radiofrequency needle applied to the facet joint (Group 2)
Number of subjects: 100
Study: 27769202

Group type: EXPERIMENTAL
Intervention: Bright Light Therapy (BLT) - 10,000 Lux
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control light condition - 200 Lux
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Bright Light Therapy (BLT)
Number of subjects: 84
Study: 25498777

Group type: EXPERIMENTAL
Intervention: Patient Perception of Intensity of Urgency Scale (PPIUS) - Total Urgency and Frequency Score (TUFS)
Number of subjects: 901

Group type: EXPERIMENTAL
Intervention: Other PPIUS-derived scores
Number of subjects: 901
Study: 23444895

Group type: EXPERIMENTAL
Intervention: Green calorie label
Number of subjects: 0

Group type: COMPARATOR
Intervention: Red calorie label
Number of subjects: 0

Group type: COMPARATOR
Intervention: White calorie label
Number of subjects: 0
Study: 19900763

Group type: EXPERIMENTAL
Intervention: AlcoholEdu
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: e-Chug
Number of subjects: 82

Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 82
Study: 18491685

Group type: EXPERIMENTAL
Intervention: Comprehensive Health Enhancement Support System (CHESS), a Web‐based information and support scheme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 16817205

Group type: EXPERIMENTAL
Intervention: 30-item Geriatric Depression Scale (GDS)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 17-item Hamilton Depression Rating Scale (HDRS)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: GDS
Number of subjects: 57
Study: 14620073

Group type: EXPERIMENTAL
Intervention: Trial participation (for randomized participants)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Screening visit (for non-participants)
Number of subjects: 58
Study: 11063182

Group type: EXPERIMENTAL
Intervention: Streptokinase (SK) 1.5 mega-units diluted in 100 mls of normal saline infused over 60 minutes (Group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (Group B) - AMI patients who did not receive SK
Number of subjects: 120
Study: 8843961

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (bleomycin, vincristine, mitolactol, methotrexate, 3 courses)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Preoperative irradiation (telecobalt, followed by surgery)
Number of subjects: 50
Study: 1441001

Group type: EXPERIMENTAL
Intervention: Early mobilization with a brace
Number of subjects: 71

Group type: COMPARATOR
Intervention: Immobilization with plaster cast
Number of subjects: 71
Study: 31650354

Group type: EXPERIMENTAL
Intervention: Daily group (DG) - melatonin supplement taken between 22:00 and 23:00 for 3 consecutive days
Number of subjects: 67

Group type: COMPARATOR
Intervention: Acute group (AG) - melatonin supplement taken after the second measure on the second day
Number of subjects: 67
Study: 28954297

Group type: EXPERIMENTAL
Intervention: AT
Number of subjects: 1512

Group type: EXPERIMENTAL
Intervention: ACT
Number of subjects: 1512

Group type: COMPARATOR
Intervention: AC→T
Number of subjects: 1512

Group type: EXPERIMENTAL
Intervention: Preexisting PN, older age, obesity, mastectomy, greater number of positive nodes
Number of subjects: 1512

Group type: EXPERIMENTAL
Intervention: Worse PN symptoms at 24 months
Number of subjects: 1512
Study: 28404197

Group type: EXPERIMENTAL
Intervention: Mercaptopurine (1 mg/kg bodyweight, rounded to nearest 25 mg)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Mercaptopurine (in smokers)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo (in smokers)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Mercaptopurine (in non-smokers)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo (in non-smokers)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Number of subjects: 240
Study: 25022690

Group type: EXPERIMENTAL
Intervention: H61-fermented milk (10^10 cfu of strain H61/d)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional yogurt (10^10 cfu of Lactobacillus delbrueckii ssp. bulgaricus and Streptococcus thermophilus per day)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: H61-fermented milk and Conventional yogurt
Number of subjects: 23
Study: 22874843

Group type: EXPERIMENTAL
Intervention: Oral sodium load
Number of subjects: 15

Group type: COMPARATOR
Intervention: Intravenous sodium load
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-sodium diet
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low-sodium diet
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Serum concentrations of prouroguanylin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Serum concentrations of proguanylin
Number of subjects: 15
Study: 20688454

Group type: EXPERIMENTAL
Intervention: Video-based education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Print-based education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Take-home print materials (for print and half of video participants)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No education (control group)
Number of subjects: 0
Study: 18721120

Group type: EXPERIMENTAL
Intervention: Manual hyperinflation with positive end expiratory pressure followed by suction
Number of subjects: 55

Group type: COMPARATOR
Intervention: Suction only
Number of subjects: 55
Study: 16422908

Group type: EXPERIMENTAL
Intervention: Labial photoplethysmograph (LP)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Vaginal photoplethysmograph (VP)
Number of subjects: 15
Study: 12865509

Group type: EXPERIMENTAL
Intervention: Lignocaine group II (0.5% lignocaine infiltration at each pin site)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group I (pins applied without any scalp infiltration)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups during pinning
Number of subjects: 30
Study: 10232413

Group type: EXPERIMENTAL
Intervention: Induced sputum in patients with OA at work
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Eosinophil cationic protein (ECP) in induced sputum in patients with OA at work
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Blood eosinophil count in patients with OA at work
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Serum ECP levels in patients with OA at work
Number of subjects: 16
Study: 8912740

Group type: EXPERIMENTAL
Intervention: PSV alone (15, 20, and 25 cm H2O)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PSV combined with PEEP of 5 cm H2O (reducing PSV to 10, 15, and 20 cm H2O)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Spontaneous breathing (SB)
Number of subjects: 8
Study: 1666933

Group type: EXPERIMENTAL
Intervention: RIBA‐2
Number of subjects: 732

Group type: COMPARATOR
Intervention: RIBA‐1
Number of subjects: 732
Study: 6132613

Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg kg‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazemuls 0.15 mg kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazemuls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 0
Study: 29618054

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 427

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Subtotal resection (STR)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Gross-total resection
Number of subjects: 427
Study: 28945493

Group type: EXPERIMENTAL
Intervention: 1.23% acidulated phosphate fluoride (APF) gel with cold atmospheric plasma (CAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1.23% acidulated phosphate fluoride (APF) gel
Number of subjects: 0
Study: 27120271

Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine gluconate (CH)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 61% ethanol solution with 1% chlorhexidine gluconate (ES/CH)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 30% 1‐propanol and 45% 2‐propanol solution (MPS)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 70% 2‐propanol solution (IPS)
Number of subjects: 45
Study: 25262168

Group type: EXPERIMENTAL
Intervention: Visual-arts based creative engagement intervention (CEI) facilitated by experienced artists, up to eight sessions (four group and four one-to-one)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 80
Study: 22362097

Group type: EXPERIMENTAL
Intervention: Titanium-nitride-oxide coated bio-active stent (BAS)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 425
Study: 20304589

Group type: EXPERIMENTAL
Intervention: Early endovascular repair
Number of subjects: 728

Group type: COMPARATOR
Intervention: Ultrasound surveillance
Number of subjects: 728
Study: 16925861

Group type: EXPERIMENTAL
Intervention: P supplement 250 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: P supplement 750 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: P supplement 1500 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (0 mg P)
Number of subjects: 14
Study: 14624045

Group type: EXPERIMENTAL
Intervention: Computer-generated acenocoumarol dosages
Number of subjects: 15940

Group type: COMPARATOR
Intervention: Traditionally fixed acenocoumarol dosages
Number of subjects: 15940
Study: 10719952

Group type: EXPERIMENTAL
Intervention: Propofol administration via target‐controlled infusion
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Propofol administration in patients older than 60 years
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Propofol administration in children
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Venous data for propofol administration
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Bolus data for propofol administration
Number of subjects: 270
Study: 9021354

Group type: EXPERIMENTAL
Intervention: Sequential step‐up and step‐down protocol
Number of subjects: 56

Group type: COMPARATOR
Intervention: Classic step‐up protocol
Number of subjects: 56
Study: 1389840

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Midazolam and Propofol combination
Number of subjects: 140
Study: 3931136

Group type: EXPERIMENTAL
Intervention: methylclonazepam 1 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: lorazepam 2.5 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 31813635

Group type: EXPERIMENTAL
Intervention: External beam accelerated partial breast irradiation (APBI) - 38.5 Gy in ten fractions delivered twice per day over 5-8 days
Number of subjects: 2135

Group type: COMPARATOR
Intervention: Whole breast irradiation - 42.5 Gy in 16 fractions once per day over 21 days or 50 Gy in 25 fractions once per day over 35 days
Number of subjects: 2135
Study: 26501196

Group type: EXPERIMENTAL
Intervention: Combat application tourniquet (CAT) applied at mid-thigh level
Number of subjects: 145

Group type: COMPARATOR
Intervention: Combat application tourniquet (CAT)
Number of subjects: 145
Study: 26133135

Group type: EXPERIMENTAL
Intervention: Anorganic bone mineral-collagen membranes (BB)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Betatricalcium phosphate-pericardium collagen membranes (CJ)
Number of subjects: 10
Study: 23352095

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer sirolimus-eluting stent (BP-SES)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Durable polymer everolimus-eluting stent (EES)
Number of subjects: 20
Study: 20937506

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 360

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 360
Study: 19823969

Group type: EXPERIMENTAL
Intervention: Modified release 100 mg lamotrigine tablet (formulations L-1, L-2, L-3)
Number of subjects: 12
Study: 17110897

Group type: EXPERIMENTAL
Intervention: Continuous intraperitoneal insulin infusion (CIpii)
Number of subjects: 275
Study: 15337326

Group type: EXPERIMENTAL
Intervention: Olanzapine (5‐20 mg) added to mood stabilizer therapy
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo added to mood stabilizer therapy
Number of subjects: 336
Study: 12230419

Group type: EXPERIMENTAL
Intervention: Extended thromboprophylaxis with warfarin for 4 more weeks
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group (stopped warfarin at hospital discharge)
Number of subjects: 360
Study: 9686768

Group type: EXPERIMENTAL
Intervention: Tolcapone 200 mg three times a day for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tolcapone with oral selegiline (5 mg in the morning and midday) during the second 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tolcapone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8134810

Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 2527935

Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 1100359

Group type: EXPERIMENTAL
Intervention: Na2PO3F toothpaste with regular tooth cleaning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group with regular but insufficient tooth cleaning
Number of subjects: 0
Study: 29722110

Group type: EXPERIMENTAL
Intervention: 8 h haemodialysis
Number of subjects: 12

Group type: COMPARATOR
Intervention: 4 h haemodiafiltration
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fresenius FX80 dialyser
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nipro Elisio
Number of subjects: 12
Study: 29231544

Group type: EXPERIMENTAL
Intervention: Acupoint embedding (once a week for 8 weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Oral lactulose (3 times a day for 8 weeks)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Acupoint embedding
Number of subjects: 56
Study: 25956020

Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWD)
Number of subjects: 338
Study: 23294293

Group type: EXPERIMENTAL
Intervention: Prion-filtered red cell concentrates (PF‐RCC)
Number of subjects: 590

Group type: COMPARATOR
Intervention: Standard red cell concentrates (RCC)
Number of subjects: 590
Study: 20850853

Group type: EXPERIMENTAL
Intervention: FOCUS harmonic scalpel (group A, n = 45)
Number of subjects: 90

Group type: COMPARATOR
Intervention: HARMONIC ACE (group B, n = 45)
Number of subjects: 90
Study: 17879256

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 16570898

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 60

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 60
Study: 14644865

Group type: EXPERIMENTAL
Intervention: Serum human cartilage glycoprotein 39 (HC gp39)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Number of affected joints (NAJ)
Number of subjects: 121
Study: 11432215

Group type: COMPARATOR
Intervention: Acetaminophen only (650 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Acetaminophen plus cooling blanket (18 degrees C)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Physical cooling only (cooling blanket at 18 degrees C)
Number of subjects: 14
Study: 9209244

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg/day during 6 days)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 8260476

Group type: EXPERIMENTAL
Intervention: Guar gum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sugar-beet fibre (SBF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wheat bran
Number of subjects: 0

Group type: COMPARATOR
Intervention: NSP-free control meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meal containing cholestyramine
Number of subjects: 0
Study: 2893564

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vecuronium 0.12 mg/kg
Number of subjects: 20
Study: 31375226

Group type: EXPERIMENTAL
Intervention: Audiovisual presentation + leaflet
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Audiovisual presentation + generic mind map
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Audiovisual presentation + customized mind map
Number of subjects: 165

Group type: COMPARATOR
Intervention: Leaflet
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Generic mind map
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Customized mind map
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Audiovisual presentation + written information methods
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Parents
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Correlation between patient and parent knowledge scores
Number of subjects: 165
Study: 29056020

Group type: EXPERIMENTAL
Intervention: Three dimensional human body scanning system BurnCalc
Number of subjects: 48

Group type: COMPARATOR
Intervention: NIH Image J method
Number of subjects: 48

Group type: COMPARATOR
Intervention: Transparency tracing method
Number of subjects: 48
Study: 24782108

Group type: EXPERIMENTAL
Intervention: Single-injection femoral nerve block (FNB) with intravenous PCA opioid
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (FNB)
Number of subjects: 200

Group type: COMPARATOR
Intervention: PCA opioid alone
Number of subjects: 200
Study: 22374331

Group type: EXPERIMENTAL
Intervention: oral sorafenib 400 mg twice a day
Number of subjects: 602

Group type: COMPARATOR
Intervention: matching placebo
Number of subjects: 602
Study: 20850133

Group type: EXPERIMENTAL
Intervention: Antioxidant beverage rich in polyphenols
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 100
Study: 17669023

Group type: EXPERIMENTAL
Intervention: rhBMP‐2/ACS (0.2 mg/mL)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: rhBMP‐2/ACS (0.56 mg/mL)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: rhBMP‐2/ACS (0.2 mg/mL) and rhBMP‐2/ACS (0.56 mg/mL)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 27
Study: 15615875

Group type: COMPARATOR
Intervention: Scaling and root planing, quadrant by quadrant, at two‐week intervals (NC)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Full‐mouth scaling and root planing within 24 hrs (FRP)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Full‐mouth disinfection within 24 hrs, including antiseptics (CHX or F for 2 mos, or CHX for 2 mos followed by F for 6 mos (CHX+F))
Number of subjects: 71
Study: 12464992

Group type: EXPERIMENTAL
Intervention: Treatment-induced decrease in mean arterial pressure (MAP)
Number of subjects: 2640

Group type: COMPARATOR
Intervention: Control of blood pressure
Number of subjects: 2640
Study: 10657735

Group type: EXPERIMENTAL
Intervention: Estradiol treatment (0.1 mg 17beta-estradiol daily via transdermal patches)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo treatment (placebo via transdermal patches)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Dexamethasone (1.5 mg) and hCRH (100 microgram)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 43
Study: 7596696

Group type: EXPERIMENTAL
Intervention: Biofeedback treatment
Number of subjects: 129

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Unsuccessful biofeedback treatment
Number of subjects: 129
Study: 2173282

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) treatment (0.4 g/kg body weight every 2 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both patient groups (IVIG and placebo)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Seropositive controls
Number of subjects: 15
Study: 7352955

Group type: EXPERIMENTAL
Intervention: 1 g vitamin C daily (Group II)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2 g vitamin C daily (Group III)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2 g vitamin C daily for the first 20 days (in a separate group of 40 patients with acute myocardial infarction)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (control group for acute myocardial infarction patients)
Number of subjects: 40
Study: 31825692

Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nivolumab and ipilimumab combination therapy
Number of subjects: 0
Study: 31150431

Group type: EXPERIMENTAL
Intervention: Early condition (participants presented with examples referring to memories from age 1-2)
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Late condition (participants presented with examples referring to memories from age 5-6)
Number of subjects: 619

Group type: COMPARATOR
Intervention: Control group (participants presented with examples that did not contain any age cues)
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Snapshot memories
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Event memories
Number of subjects: 619
Study: 28086896

Group type: EXPERIMENTAL
Intervention: Fast-track surgery (FTS)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional management (control)
Number of subjects: 35
Study: 26604721

Group type: EXPERIMENTAL
Intervention: GCQID group (1,200 mg glucosamine hydrochloride, 60 mg chondroitin sulfate, 45 mg type II collagen peptides, 90 mg quercetin glycosides, 10 mg imidazole peptides, 5 μg vitamin D per day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: GCQID group
Number of subjects: 100